Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes

Kentaro Tanaka1, Shigeko Hara1, Masakazu Hattori2, Ken Sakai3, Yukiko Onishi1, Yoko Yoshida1, Shoji Kawazu1, Akifumi Kushiyama1*

1Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, 2Department of Nephrology, School of Medicine, Faculty of Medicine, Toho University, Tokyo, and 3Division of Diabetes, Clinical Research Center for Endocrinology and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan

Keywords
Risk factors, Type 2 diabetic nephropathy, Uric acid

*Correspondence
Akifumi Kushiyama
Tel.: +81-3-3639-5501
Fax: +81-3-3639-5520
E-mail address: a-kushiyama@asahi-life.or.jp

J Diabetes Invest 2015; 6: 98–104
doi: 10.1111/jdi.12243

ABSTRACT
Aims/Introduction: Despite the use of intensive therapies, declining renal function is often observed during the overt nephropathy stage of type 2 diabetes. We aimed at investigating the role of serum uric acid (SUA) levels at the onset of overt nephropathy in the risk of renal function decline in type 2 diabetes patients.

Materials and Methods: The present cohort study included 290 type 2 diabetes patients who were followed from the onset of overt nephropathy. The relationship between SUA and declining renal function was assessed using Cox regression models after adjusting for known risk factors.

Results: Over a median 4.8-year follow-up period, 85 patients (4.9/100 person-years) showed serum creatinine (Cr) doubling with a total cumulative incidence of 71.9% at 20 years of follow up. The highest SUA tertile resulted in significantly a higher incidence (7.7/100 person-years) and cumulative incidence at 20 years (85.7%) than the middle (3.9/100 person-years, 54.2%) and lowest (3.0/100 person-years, 55.5%) tertiles. The univariate Cox hazard model resulted in significant risks for Cr doubling related to female sex, short diabetes duration, smoking and elevated levels of low-density lipoprotein cholesterol (LDL-c), glycated hemoglobin and SUA tertiles. SUA tertiles remained statistically significant in the multivariate model (highest vs lowest hazard ratio 2.68, 95% confidence interval 1.48–5.00, P = 0.0009).

Conclusions: Elevated SUA levels within the normal range (men >6.3 mg/dL, women >5.1) at the onset of overt nephropathy resulted in an increased risk for declining renal function in type 2 diabetes patients.

INTRODUCTION
Nephropathy related to type 2 diabetes is one of the leading causes of end-stage renal disease (ESRD), and is also associated with an increased risk of cardiovascular morbidity and mortality. Over the past 15 years, it has emerged as the primary reason for initiating dialysis in Japan1. Modifiable factors, such as arterial blood pressure, albuminuria, glycemic control and lipid control, play a role in the progression of diabetic nephropathy2.

In the early microalbuminuria stage, intensive multifactorial therapy that includes glycemic, lipid and blood pressure control, in addition to smoking cessation, has induced remission and improved renal function3,4. There is little evidence of the contribution of these factors in the prevention of the progressive loss of renal function in advanced diabetic nephropathy5. The evidence is limited to the effect of hypertension management and
a low-protein diet\textsuperscript{6}. Despite the use of these intensive therapies, the loss of renal function progresses, after the onset of overt nephropathy, to ESRD in the majority of cases. One study reported that various early biomarkers are associated with the development of diabetic nephropathy\textsuperscript{7}.

Recent studies have documented that elevated serum uric acid (SUA) levels are positively associated with the development of type 2 diabetes itself\textsuperscript{6}. SUA is also associated with known risk factors for kidney disease progression\textsuperscript{9}, including hypertension\textsuperscript{10}, cardiovascular disease\textsuperscript{11-13} and atherosclerosis\textsuperscript{12}. SUA has not been investigated as a risk factor for declining renal function in patients with type 2 diabetes who are at the onset of overt nephropathy, although SUA was previously reported in the early stage of diabetic nephropathy\textsuperscript{14}.

The present study aimed to determine the role of SUA levels at the onset of overt nephropathy in the risk of renal function decline in patients with type 2 diabetes.

**METHODS**

**Study Design and Participants**

The present study was a retrospective, observational cohort study of patients with type 2 diabetes attending the Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan. The protocol was approved by the Committee of Ethics in this institution. Patients gave informed consent.

The inclusion criteria included the following: (i) aged $\geq 18$ years; (ii) attending the hospital outpatient clinic for treatment of type 2 diabetes; (iii) diagnosis of diabetic nephropathy between January 1969 and December 2008.

Diabetic nephropathy was clinically diagnosed using the following criteria\textsuperscript{15}: (i) diabetes duration $>10$ years; (ii) diabetic retinopathy before the onset of overt proteinuria; and (iii) persistent albuminuria with no evidence of other kidney or urological disease. The onset of overt nephropathy was defined as the data of first urinary albumin/creatinine ratio $\geq 300$ mg/g creatinine (Cr) or positive proteinuria by dipstick analysis examination. The albuminuria or proteinuria was confirmed by repeated testing on a different day, and the follow-up period started. Diabetic retinopathy was diagnosed as retinal bleeding and was confirmed by an ophthalmologist. From these criteria, 313 patients were included.

The exclusion criteria included the following: (i) undefined history of nephropathy onset; (ii) patients with other kidney or urological disease; and (iii) patients with another cause of proteinuria, such as acute infectious disease and heart failure. Patients with hypertension were not excluded if there was no evidence of a causal role of hypertension in proteinuria.

We excluded 23 patients with an undefined history of nephropathy onset. The remaining 290 patients (231 men and 59 women, age 35–94 years, median follow-up period 4.8 years) comprised the sample for the present study, and were followed from the onset of nephropathy until October 2009. The patients were grouped according to changes in serum Cr from the baseline values: the Cr doubling group (doubling of serum Cr) and the non-doubling group.

**Clinical Measurements**

The following data were collected: age (years), body mass index (BMI; kg/m$^2$), diabetes duration (years), systolic and diastolic blood pressure (mmHg), glycated hemoglobin (HbA1c %), high-density lipoprotein-cholesterol (HDL-C; mg/dL), low-density lipoprotein-cholesterol (LDL-C; mg/dL), triglycerides (mg/dL), SUA (mg/dL), Cr (mg/dL), estimated glomerular filtration rate (eGFR; mL/[min·1.73 m$^2$]), hemoglobin (g/dL), smoking status (yes/no) and medication usage. HbA1c values were converted as previously described\textsuperscript{16,17}. A turbidimetric immunoassay (Code 468-34691; Wako Pure Chemical Industries, Ltd, Osaka, Japan) was used for the measurement of urinary albumin. The eGFR was calculated using the estimation formula advocated by the Japanese Society of Nephrology\textsuperscript{18}: eGFR (mL/[min·1.73 m$^2$]) $= 194 \times$ Cr$^{-1.094} \times$ age$^{-0.287}$ ($\times$0.739 for female patients). In the case of serum creatinine concentration being measured by Jaffe assay, the enzymatic value was estimated using the following equation: serum creatinine enzyme $= 0.977 \times$ serum creatinine Jaffe $- 0.199$ (given in mg/dL)\textsuperscript{19}. Proteinuria was examined by dipstick analysis, semi-quantitatively defined as ‘+’, which indicated approximately 30 mg/dL, approximately 0.3 g/day urinary protein excretion; ‘2+’ 100 mg/dL, approximately 1 g/day; and ‘3+’ $\geq 300$ mg/dL, approximately 3 g/day, respectively\textsuperscript{20}. All laboratory data were measured under the right conditions (without gout and change of prescription).

**Definitions**

Decline in renal function was defined as the doubling of serum Cr. Hypertension was defined as a systolic blood pressure $\geq 130$ mmHg and/or a diastolic blood pressure $\geq 80$ mmHg and/or the current use of antihypertensive medication. Dyslipidemia was defined as a LDL-C level $\geq 120$ mg/dL, HDL-C level $< 40$ mg/dL and/or the current use of lipid-lowering medication. Hyperuricemia was defined as a SUA level $\geq 7.0$ mg/dL, approximately 1 g/day; and ‘3+’ $\geq 300$ mg/dL, approximately 3 g/day, respectively\textsuperscript{20}. All laboratory data were measured under the right conditions (without gout and change of prescription).

Coronary heart disease (CHD) was defined as myocardial infarction, and angina pectoris was confirmed by coronary intervention. Stroke was defined as bleeding, and ischemic stroke included lacunar infarctions with symptoms confirmed by brain computed tomography (CT) or magnetic resonance imaging (MRI). Arteriosclerosis obliterans (ASO) was diagnosed using angiography with enhanced CT or MRI and/or an ankle-brachial pressure index (ABI) $< 0.9$. Aortic calcification was confirmed by chest radiography.

**Statistical Analysis**

The data are expressed as mean $\pm$ standard deviation (SD). The differences between the two groups were assessed using unpaired Student’s $t$-tests for continuous variables and
chi-squared tests for categorical variables. The relationship between SUA levels and residual renal function (eGFR) was analyzed using Spearman’s correlation analysis. SUA levels were stratified into tertiles, which were calculated separately for men (lower tertile: <310 μmol/L [5.2 mg/dL]; middle: 310–380 μmol/L [5.2–6.3 mg/dL]; upper: >380 μmol/L [6.3 mg/dL]) and women (lower tertile: <244 μmol/L [4.1 mg/dL]; middle: 244–303 μmol/L [4.1–5.1 mg/dL]; upper: >303 μmol/L [5.1 mg/dL], respectively), because SUA levels in women tend to be lower than those in men.

Decline in renal function (doubling of serum Cr) was analyzed using the Kaplan–Meier method, and the significance was calculated using the log–rank test. Cox proportional hazards regression modeling was used to assess the independent risk factors for Cr doubling. The multivariate model accounted for baseline values of age (years), sex (men vs women), diabetes duration (years), smoking status (yes/no), BMI (kg/m²), HbA1c (%), systolic blood pressure (mmHg), LDL-C (mg/dL), use of medical agents (antiplatelet, antihyperuricemic, antihypertensive or lipid lowering medication), eGFR (ml/[(min•1.73 m²)], proteinuria (1+, 2+, 3+) and SUA. These results are presented as hazard ratios (HR) with 95% confidence intervals (95% CI). HRs for continuous variables are described against a 1-SD change. Furthermore, P-values <0.05 were considered to be statistically significant. Analyses were carried out using JMP software (version 9.0; SAS Institute, Cary, NC, USA).

Power Calculation
We are planning a study with 96 experimental participants, 96 control participants, an accrual interval of 0 years, and additional follow up of a median of 4.8 years. In a previous study, the median survival time on the control treatment was 5 years. If the true hazard ratio of control participants relative to experimental participants is 2, we will be able to reject the null hypothesis that the experimental and control survival curves are equal with probability (power) 0.871. The type I error probability associated with this test of the null hypothesis is 0.05.

RESULTS
The demographic and clinical characteristics of the 290 patients at baseline are shown in Table 1. The mean age of study participants was 61.9 ± 9.8 years, the mean diabetes duration was 18.0 ± 8.5 years and the mean duration of study follow up was 5.8 ± 4.1 years. The baseline biochemical and clinical characteristics of the patients in their respective groups (Cr doubling or non-doubling) are also shown in Table 1. A total of 135 patients were treated with insulin, and 144 patients were treated with diet therapy and oral hypoglycemic drugs at the baseline. As compared with the non-doubling group, the Cr doubling group was significantly younger, with a significantly shorter duration of diabetes; however, the Cr doubling group showed a significantly more severe pathological state (higher HbA1c levels, more overt proteinuria, major angiopathy and higher SUA levels).

Figure 1 shows the results of the Kaplan–Meier survival analysis for the incidence of Cr doubling. A total of 85 (29.3%) of the 290 patients showed Cr doubling during the follow-up period (median 4.8 years, range 0–22 years), resulting in an incidence of 4.9 out of 100 person-years and a total cumulative incidence of 71.9% at 20 years of follow up. Analysis according to the baseline SUA tertiles resulted in an incidence and cumulative incidence of Cr doubling at 20 years of 3.0 out of 100 person-years and 55.5% in the lowest tertile, 3.9 out of 100 person-years and 54.2% in the middle tertile, and 7.7 out of 100 person-years and 85.7% in the highest tertile. Patients in the highest tertile had a significantly higher risk of Cr doubling than those in the lower two tertiles (log–rank test, P = 0.0008).

The results from the univariate Cox regression analyses are shown in Table 2. Cr doubling was significantly associated with sex (women HR 2.28, 95% CI 1.42–3.57, P = 0.0009), diabetes duration (HR 0.95, 95% CI 0.93–0.98, P = 0.004), LDL-C (HR 1.00, 95% CI 1.00–1.01, P = 0.03), smoking status (yes HR 2.17, 95% CI 1.40–3.43, P = 0.0005), HbA1c levels (HR 1.32, 95% CI 1.19–1.46, P < 0.0001), eGFR (HR 1.01, 95% CI 1.00–1.02, P = 0.01) and SUA tertiles (main effect P = 0.001; highest vs middle HR 1.87, 95% CI 1.12–3.23, P = 0.01; middle vs lowest HR 1.35, 95% CI 0.71–2.59, P = 0.34; highest vs lowest HR 2.54, 95% CI 1.50–4.50, P = 0.0004). Of note, the highest tertile for SUA was a strong risk factor for declining renal function, even though 86.2% of the patients in the highest SUA tertile had borderline normal levels (6.3–7.0 mg/dL in men and 5.1–7.0 mg/dL in women). Age, BMI, systolic blood pressure, use of antiplatelet agents, use of antihypertensive agents, use of statin, degree of proteinuria and a previous history of coronary heart diseases were not significant risk factors. Furthermore, a previous history of stroke and ASO, and aortic calcification were not significant (data not shown).

In the multivariate Cox regression analysis, model 1 includes parameters only significant in the univariate model and model 2 includes all. In model 1, the risks for Cr doubling included sex, smoking status, HbA1c levels and SUA tertiles (main effect: P = 0.008; highest vs lowest HR 2.37, 95% CI 1.35–4.30, P = 0.002; highest vs middle HR 1.70, 95% CI 0.88–3.31, P = 0.11; middle vs lowest HR 1.39, 95% CI 0.81–2.46, P = 0.23) remained significant. In model 2, the risks for Cr doubling included smoking status (yes HR 1.74, 95% CI 1.07–2.87, P = 0.02), HbA1c levels (HR 1.25, 95% CI 1.09–1.42, P = 0.0009) and SUA tertiles (main effect P = 0.003; highest vs lowest HR 2.68, 95% CI 1.48–5.00, P = 0.0009; highest vs middle HR 1.70, 95% CI 0.88–2.86, P = 0.12; middle vs lowest HR 1.57, 95% CI 0.86–3.40, P = 0.12). The highest SUA remained significant after adjustment for confounding variables.

In the non-doubling group, there was a significant (r = 0.35, P < 0.0001) correlation between eGFR and SUA, but the same relationship was not significant (r = 0.20, P = 0.062) in the doubling group (Figure 2a,b).
Table 1 | Demographics and clinical characteristics of participants at the start of follow up

| Demographics and clinical characteristics | Total sample (n = 290) | Cr doubling group (n = 85) | Non-doubling group (n = 205) | P-value

| Male/female | 231/59 | 58/27 | 173/32 |
| Age (years) | 61.9 ± 98 | 584 ± 10 | 633 ± 66 | <0.0001 |
| Diabetes duration (years) | 18.0 ± 85 | 146 ± 0.8 | 195 ± 0.5 | <0.0001 |
| Body mass index (kg/m²) | 23.9 ± 3.4 | 235 ± 0.3 | 240 ± 0.2 | 0.209 |
| Systolic BP (mmHg) | 139.6 ± 192 | 1394 ± 2.0 | 139.6 ± 1.3 | 0.943 |
| Diastolic BP (mmHg) | 76.6 ± 117 | 771 ± 1.2 | 764 ± 0.8 | 0.659 |
| HbA1c (%) | 8.68 ± 185 | 96 ± 0.18 | 82 ± 0.12 | <0.0001 |
| HDL-C (mg/dL) | 521 ± 155 | 51.4 ± 69 | 523 ± 109 | 0.642 |
| LDL-C (mg/dL) | 1187 ± 328 | 1265 ± 3.5 | 115.5 ± 2.2 | 0.0088 |
| Triglycerides (mg/dL) | 1621 ± 1660 | 1710 ± 11.5 | 1584 ± 7.4 | 0.356 |
| Uric acid (mg/dL) | 5.47 ± 137 | 6.02 ± 0.14 | 5.25 ± 0.09 | <0.0001 |
| Creatinine (mg/dL) | 0.87 ± 024 | 0.82 ± 0.02 | 0.88 ± 0.01 | 0.062 |
| eGFR (mL/min/1.73 m²) | 804 ± 242 | 84.7 ± 2.6 | 78.7 ± 1.6 | 0.054 |
| Hemoglobin (g/dL) | 41.4 ± 15 | 139 ± 0.17 | 142 ± 0.11 | 0.054 |
| Proteinuria (1+, 2+, 3+) (%) | 91.4, 50.7, 176 | 9.4, 41, 17.6 | 41.4, 546, 39 | 0.0003 |
| Smoking status, % (n) | 45.5 (132) | 64.7 (55) | 37.5 (77) | <0.0001 |
| Hypertension, % (n) | 87.5 (254) | 835 (71) | 892 (183) | 0.177 |
| Dyslipidemia, % (n) | 73.7 (214) | 729 (62) | 74 (152) | 0.883 |
| Hyperuricemia, % (n) | 25.8 (75) | 44.7 (38) | 18.0 (37) | <0.0001 |
| Antiplatelet agent use, % (n) | 21.7 (63) | 188 (16) | 22.9 (47) | 0.532 |
| Antihypertensive agent use, % (n) | 66.5 (193) | 576 (49) | 70.2 (144) | 0.041 |
| Renin-angiotensin system inhibitors, % (n) | 46.2 (134) | 34.1 (29) | 51.2 (105) | 0.007 |
| Statin use, % (n) | 296 (86) | 200 (17) | 33.6 (69) | 0.023 |
| Antihyperuricemia agent use, % (n) | 96 (28) | 105 (9) | 9 (19) | 0.827 |
| CHD, % (n) | 16.8 (49) | 28.2 (24) | 12.2 (25) | 0.0017 |
| Stroke, % (n) | 14.4 (42) | 223 (19) | 11.2 (23) | 0.017 |
| ASO, % (n) | 9.3 (27) | 164 (14) | 6.3 (13) | 0.012 |
| Aortic calcification, % (n) | 16.2 (47) | 270 (23) | 11.7 (24) | 0.0025 |

ASO, arteriosclerosis obliterans; BP, blood pressure; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The statistical significance was estimated using independent Student’s t-tests for continuous variables and chi-squared tests for categorical variables (P < 0.05). Comparisons were made between the creatinine (Cr) doubling group and the non-doubling group. Values are reported as mean ± standard deviation or as % (n), where indicated.

**DISCUSSION**

To our knowledge, this is the first report to show SUA levels at the onset of overt nephropathy as a risk factor for declining renal function in patients with type 2 diabetes. An elevated SUA level within the normal range (>380 μmol/L [6.4 mg/dL]) in men, >303 μmol/L [5.1 mg/dL] in women) emerged as a strong and independent risk factor for renal function decline.

These findings complement those reported previously in type 1 diabetes regarding the significant predictive abilities of UA for the development of diabetic nephropathy[^23][^24].

Renal condition at baseline, measured as the eGFR, is another important predictor of the decline in renal function. Generally, low eGFR is considered a risk factor for the progression of renal dysfunction[^25]. However, in patients with type 2 diabetes, glomerular hyperfiltration and the accompanying increase in eGFR, which is observed in 0–40% of patients with type 2 diabetes[^26], contributes to loss of renal function and nephropathy[^27]. Similarly, in the current study, increased eGFR at baseline was a significant risk factor for impaired renal function in the univariate analysis, and we hypothesize that the eGFR would continue to increase in the high-risk group, if the follow up continued.

Elevated SUA levels have previously been associated with eGFR, albeit with decreased eGFR[^28]. SUA levels are determined by UA production and excretion, and UA is produced by xanthine oxidoreductase. Oxidoreductase activity also contributes to macrophage foam cell formation and inflammation[^29], and macrophage activation is thought to be involved in the pathogenesis of overt nephropathy[^30]. Therefore, UA production might be assessed using SUA and eGFR, which could be a diagnostic and monitoring marker for renal injury.

The target SUA value for therapeutic intervention has not been clarified to prevent renal function decline or arteriosclerosis. It is speculated from the present results and previous small size, short-term intervention studies including non-diabetic patients that UA-lowering treatment has a renoprotective effect, and inhibits oxidative stress, atherogenesis, hypertension and vascular endothelial damage[^31][^32]. The use of UA-lowering...
treatment for renoprotection has not been incorporated into existing guidelines; instead, elevated SUA has historically been addressed only as a means to prevent gout attacks.34.

The recommended multifactorial management of type 2 diabetic nephropathy is to stop smoking35 and to maintain the following: blood pressure <130/85 mmHg, HbA1c <7.0% and LDL-C <100 mg/dL.36 Of these, poor glycemic control, elevated LDL-C and smoking, but not high blood pressure, were significant risk factors for renal dysfunction in the current study. In addition to these known factors, SUA also probably increased the risk of declining renal function. Further evidence for the use of UA-lowering treatment for renoprotection is required.

The present study had several limitations. First, this was a retrospective observational study carried out in a single institution. A large-scale intervention is required to verify the effectiveness of UA-lowering therapy for renoprotection. Second, the artificial conversion between serum creatinine values obtained in different periods was a limitation. Furthermore, we did not evaluate the available types of antihypertensive agents, which might affect SUA levels. The existence of nephrosclerosis was not fully denied in the present study, because not all patients underwent kidney biopsy.

Despite these limitations, the long-term follow up in the current study provides a certain level of confidence in using the results to refine the therapeutic approaches for overt nephropathy with the aim of preventing the progression to ESRD. Interventions to address elevated SUA levels, even within the

---

**Table 2 | Risk factors of creatinine doubling as assessed by Cox proportional hazards models**

| Variable                        | Univariate | Multivariate model 1 | Multivariate model 2 |
|---------------------------------|------------|----------------------|----------------------|
|                                 | HR (95% CI) | P                    | HR (95% CI) | P | HR (95% CI) | P |
| SUA tertiles                    |            |                      |            |   |            |   |
| Highest (T3) vs middle (T2)     | 1.87 (1.12–2.32) | 0.01     | 1.70 (0.88–3.31) | 0.11 | 1.70 (0.86–3.40) | 0.12 |
| Middle (T2) vs lowest (T1)      | 1.35 (0.71–2.59) | 0.34     | 1.39 (0.81–2.46) | 0.23 | 1.57 (0.88–2.87) | 0.12 |
| Highest (T3) vs lowest (T1)     | 2.54 (1.50–4.50) | 0.0004   | 2.37 (1.35–4.30) | 0.002 | 2.68 (1.48–5.00) | 0.0009 |
| Age (years)                     | 0.97 (0.95–1.00) | 0.12   |                       |   | 1.01 (0.97–1.05) | 0.46 |
| Sex (women)                     | 2.28 (1.42–3.57) | 0.0009 | 1.65 (0.98–2.71) | 0.05 | 1.64 (0.92–2.86) | 0.08 |
| Diabetes duration (years)       | 0.95 (0.93–0.98) | 0.004   | 0.97 (0.94–1.00) | 0.13 | 0.96 (0.93–1.00) | 0.06 |
| Smoking status                  | 2.17 (1.40–3.43) | 0.0005 | 1.76 (1.12–2.84) | 0.01 | 1.74 (1.07–2.87) | 0.02 |
| Body mass index (kg/m²)         | 0.98 (0.90–1.06) | 0.66    |                       |   | 0.92 (0.84–1.00) | 0.06 |
| HbA1c (%)                       | 1.32 (1.19–1.46) | <0.0001 | 1.21 (1.08–1.36) | 0.001 | 1.25 (1.09–1.43) | 0.001 |
| Systolic blood pressure (mmHg)  | 0.99 (0.98–1.00) | 0.39    | 1.00 (0.99–1.00) | 0.34 | 1.00 (0.99–1.01) | 0.15 |
| LDL-C (mg/dL)                   | 1.00 (1.00–1.01) | 0.03     | 1.00 (0.99–1.00) | 0.34 | 1.00 (0.99–1.01) | 0.15 |
| Antihyperemic agents            | 0.76 (0.42–1.28) | 0.32     | 0.76 (0.40–1.37) | 0.38 | 0.76 (0.40–1.37) | 0.38 |
| Antihyperemic agents            | 0.97 (0.45–1.84) | 0.94     | 1.54 (0.69–3.04) | 0.26 | 1.54 (0.69–3.04) | 0.26 |
| Antihyperemic agents            | 0.80 (0.52–1.24) | 0.31     | 1.09 (0.65–1.84) | 0.73 | 1.09 (0.65–1.84) | 0.73 |
| Antihyperemic agents            | 0.80 (0.45–1.34) | 0.41     | 0.91 (0.50–1.58) | 0.76 | 0.91 (0.50–1.58) | 0.76 |
| eGFR (mL/min/1.73 m²)           | 1.01 (1.00–1.02) | 0.01     | 1.00 (0.99–1.01) | 0.05 | 1.01 (1.00–1.02) | 0.05 |
| Proteinuria                     | 1.09 (0.75–1.57) | 0.62     | 0.87 (0.59–1.27) | 0.48 | 0.87 (0.59–1.27) | 0.48 |
| CHD                             | 1.24 (0.77–1.96) | 0.35     | 0.98 (0.59–1.55) | 0.95 | 0.98 (0.59–1.55) | 0.95 |

Results are expressed as hazard ratios (95% confidence intervals [CI]). The hazard ratio (HR) for continuous variables was computed for 1 standard deviation change. Cohort size, n = 290 (male : female, 231:59). CHD, coronary heart disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SUA, serum uric acid. T1, first tertile; T2, second tertile; T3, third tertile.

---

**Figure 1 | Kaplan–Meier curves for the doubling of serum creatinine (Cr) in 290 patients with type 2 diabetes and overt nephropathy stratified by sex-specific tertiles (T1, T2, T3) of serum uric acid (SUA) levels. Tertiles of SUA levels: T1 (n = 99): SUA <5.2 mg/dL (men), <4.1 mg/dL (women). T2 (n = 98): SUA 5.2–6.3 mg/dL (men), 4.1–5.1 mg/dL (women). T3 (n = 93): SUA >6.3 mg/dL (men), >5.1 mg/dL (women).**
normal range, in patients with type 2 diabetes might include appropriate renoprotective therapy.

ACKNOWLEDGMENTS
The authors thank Mineko Okayasu for her programming efforts. The authors declare no conflict of interest.

REFERENCES
1. Wakisaka K, Nakai S, Kikuchi K, et al. Trends in incidence of end-stage renal disease in Japan, 1983–2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004; 19: 2044–2052.
2. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702–709.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.
4. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861.
5. Pistrosch F, Passauer J, Herbrig K, et al. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 2012; 44: 914–918.
6. Hansen HP, Tauber-Lassen E, Jensen BR, et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62: 220–228.
7. Wu J, Ding Y, Zhu C, et al. Urinary TNF-alpha and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp Ther Med 2013; 6: 1482–1488.
8. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737–1742.
9. Merjanian R, Budoff M, Adler S, et al. Coronary artery, aortic wall, and valvular calcification in nondiabetic individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64: 263–271.
10. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 308–313.
11. Zoppini G, Targher G, Negri C, et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 2009; 32: 1716–1720.
12. Tavil Y, Kaya MG, Oktar SO, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008; 197: 159–163.
13. Tanaka K, Hara S, Kushiyama A, et al. Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol 2011; 15: 391–397.
14. Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2–7.
15. Fleige J, Johnson RJ, Feehally J. Comprehensive Clinical Nephrology, 4th edn. Section 5 diabetic nephrology 2010, Mosby, Missouri, 359–376.
16. Kushiyama A, Yoshida Y, Kikuchi T, et al. Twenty-year trend of increasing obesity in young patients with poorly controlled type 2 diabetes at first diagnosis in urban Japan. J Diabetes Invest 2011; 4: 540–545.
17. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39–40.
18. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.

19. Horio M, Orita Y. Comparison of Jaffe rate assay and enzymatic method for the measurement of creatinine clearance. Nihon Jinzo Gakkai Shi 1996; 38: 296–299.

20. Meyer NL, Mercer BM, Friedman SA, et al. Urinary dipstick protein: a poor predictor of absent or severe proteinuria. Am J Obstet Gynecol 1994; 170: 137–141.

21. Akizuki S. Serum uric acid levels among thirty-four thousand people in Japan. Ann Rheum Dis 1982; 41: 272–274.

22. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

23. Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668–1671.

24. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337–1343.

25. Chang TI, Li S, Chen SC, et al. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013; 61: S4–S11.

26. Jerums G, Premaratne E, Panagiotopoulos S, et al. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010; 53: 2093–2104.

27. Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35: 2061–2068.

28. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239–247.

29. Kushiyama A, Okubo H, Sakoda H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol 2012; 32: 291–298.

30. Lan HY, Bacher M, Yang N, et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997; 185: 1455–1465.

31. Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J 2013; 77: 2043–2049.

32. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51–59.

33. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388–1393.

34. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431–1446.

35. Gambaro G, Bax G, Fusaro M, et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001; 14: 337–342.

36. Seaquist ER, Ibrahim HN. Approach to the patient with type 2 diabetes and progressive kidney disease. J Clin Endocrinol Metab 2010; 95: 3103–3110.